Alpha-Lipoic Acid: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Pharmacology & Pharmacy
Contributor:
Ferdinando Nicoletti
,
Stela Dragomanova
,
Hristian Staykov

Alpha-lipoic acid (LA) is a powerful endogenous and exogenous antioxidant. It is a disulfide compound soluble in both water and oil.

  • alfa-lipoic acid
  • antioxidants
  • natural products
  • viral infections
  • COVID-19

1. Beneficial Effects of LA

LA is a powerful endogenous and exogenous antioxidant. It is a disulfide compound soluble in both water and oil. The reduced form of LA, dihydrolipoic acid, represents the active metabolite (Figure 1).
Antioxidants 10 01294 g001 550
Figure 1. The chemical structure of lipoic acid and its active metabolite dihydrolipoic acid (https://www.robertbarrington.net/alpha-lipoic-acid-antioxidant/; posted on 3 January 2014 by Robert Barrington (accessed on 5 February 2021)).
In the cell, LA increases the utilization of glucose in the mitochondria via supplying acetyl-CoA for the production of acetylcholine [1]. LA induces the activity of the enzymes responsible for the synthesis of GSH and other antioxidant enzymes and is a cofactor of several mitochondrial enzymes [2]. Hence, LA regulates several processes, such as nucleic acid synthesis and energy production, via the citric acid cycle [2].
LA is a naturally occurring molecule, widely available as a nutraceutical. It has numerous and diverse biological activities. As a free radical scavenger, LA increases the level of reduced GSH. Moreover, it regenerates vitamins C and E as part of the antioxidant defense system.
LA stimulates insulin production and improves glucose utilization, thus ameliorating the oxidative damage caused by hyperglycemia [3]. In addition, it reduces insulin resistance and improves insulin sensitivity and blood sugar control [4]. In patients with type 1 diabetes mellitus, LA leads to the downregulation of nuclear factor-kB in monocytes [5].
Additionally, LA has been shown to improve the symptoms of diabetic neuropathy, to reduce the risk of diabetic retinopathy [6][7][8], and to ameliorate diabetes-associated autonomic neuropathy [9].
Furthermore, LA improves endothelial dysfunction [10] and decreases the risks of heart attack and stroke [11].
LA can cross the blood-brain barrier (BBB) [1][12] and may alleviate the neuroinflammatory damage, preventing neuronal death, in models of Alzheimer’s disease and Parkinson’s disease [13][14][15][16][17]. Additionally, it significantly attenuates the inflammatory response in microglial cells, downregulating the production of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and IL-6, and other cytotoxic molecules, such as nitric oxide and ROS [18].
Maldonado-Rojas and colleagues (2011) performed an in silico screening of the molecular targets for LA, and, among several targets, leukotriene A4 hydrolase, voltage-gated potassium channel, alpha hydroxysteroid dehydrogenase, and epoxide hydrolase were found to be the most likely bound by LA. As these genes are involved in the pathogenesis of a number of diseases, this finding supports the potential use of LA in the treatment of cancer, diabetes, and neurological and cardiovascular disorders [19].
The proposed mechanisms of action for LA are summarized in Table 1.
Table 1. Proposed mechanisms of action of LA.

2. Effects of LA in Viral Infection

2.1. Effects of LA on Influenza Virus Infection

Influenza viruses are RNA viruses of the Orthomyxoviridae family. Seasonal epidemics are associated with 3–5 million cases of severe illness each year and from 290- to 650-thousand deaths worldwide (https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal); accessed on 3 August 2021). Although safe and effective vaccines are available, their specificity is limited because of the diversity of the circulating influenza strains and the ability of the virus to acquire mutations. The treatment options for influenza infections are limited to inhibitors of neuraminidase and blockers of the M2 proton channel. In patients infected with IV, marked increases of oxidation byproducts are found, including 8-hydroxydeoxyguanosine, malondialdehyde, F2-isoprostane, 7-ketocholesterol, and 7β-hydroxycholesterol (reviewed in reference [20]). Additionally, elevated levels of sterol oxidation products are observed up to three months after IV clearance (reviewed in reference [20]). Finally, increased levels of ROS, as well as of nitric oxide synthase 2 (iNOS) and nitrotyrosine, are found in the lung tissues of patients that died from an IV infection (reviewed in reference [20]). Several reports have shown that NAC, ascorbic acid, and vitamin E have positive effects on IV infections by inhibiting viral replication and inflammation both in the cells and in the mice (reviewed in reference [20]). In an in vitro study, LA inhibited IV replication in MDCK cells and reduced the nuclear translocation of NF-κB. Additionally, the caspase-3 activity was remarkably inhibited, and type I interferons (IFNs) were upregulated upon LA treatment [21]. Overall, the available data indicated that LA might be a potential anti-influenza agent, deserving further investigation.

2.2. Effects of LA in Herpes Infections

Herpes virus infection is widely spread, as estimates show that 80% of people worldwide are carriers of at least one strain. Nine herpesvirus types are known to primarily infect humans: herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus, Epstein–Barr virus, human cytomegalovirus human herpesvirus 6A and 6B (HHV-6A and HHV-6B), human herpesvirus 7 (HHV-7), and Kaposi’s sarcoma-associated herpesvirus (KSHV) [22].
LA has been recognized for its potential to control herpes virus infections in a patented invention—a formulation for external use containing different naturally occurring substances, together with LA. The expected beneficial effect is to narrow the period of inflammation, allowing the affected tissues to be restored (US patent application No.: US 2011/0229584A1).
The neuroprotective properties of LA could potentially find their role in post-herpetic neuralgia, following shingles or Herpes zoster infection [12][17]. The chronic damage caused by the virus results in so-called post-herpetic neuralgia that could potentially be alleviated thanks to the neuroprotective properties of LA, which have been demonstrated in diabetic polyneuropathy—another condition related to peripheral nerve damage. In addition, by acting on the endothelial cells, LA improves the endoneurial blood flow and favors the transport of nutrients to the compression site responsible for neuronal damage [10].

2.3. Effects of LA in Viral Hepatitis

Chronic viral hepatitis is the leading cause of liver fibrosis and cirrhosis. Replication of the virus in liver cells results in decreased levels of glutathione in hepatocytes. The viral load in hepatitis C is directly related to glutathione levels [23]. Eventually, the resulting increase in oxidative stress levels leads to necrotic inflammation and the necrosis of liver cells. Increased lipid peroxidation leads to hepatic cytotoxicity, causing immune-mediated inflammation and fibrosis [24][25][26]. Supportive therapeutic effects of LA have been demonstrated in the clinical setting in patients with a Hepatitis C infection [27][28]. The LA antioxidant properties have been recognized as potential therapeutic effects based on its ability to exert anti-inflammatory, antifibrotic, and anti-TNF-α effects that produce a restoration of the damaged areas of the liver, as well as its function, as demonstrated in HCV patients [27][28]. According to a clinical study with a small number of patients conducted by Berkson in 1999, therapy with the antioxidant LA, the hepatoprotector silymarin, and the element selenium, completely restores the liver function of patients, and the proposed combination allows avoiding liver transplantation [27]. The beneficial effect of the application of various antioxidants, including LA, was later confirmed in a clinical trial enrolling 50 patients with chronic hepatitis C infection [28]. Among them, 48% responded with improvement in at least one of the observed liver parameters, and a decrease in the viral load was observed in 25% of the patients.

2.4. Effects of LA in HIV Infection

A major pathogenetic factor in HIV infection is the induced oxidative stress, which causes apoptosis and a decrease in the number of CD4 + T cells, which may eventually lead to marked immunosuppression [29][30]. Increased oxidative reactions [29] and higher concentrations of hydrogen peroxide [31] and MDA [32], as well as suppression of the antioxidant protection response, with decreased activity of the antioxidant enzymes SOD, GPx, CAT, and thioredoxin, have been found in the plasma, lung mucosa, erythrocytes, and lymphocytes from patients with HIV infection [30][31][33].
The potential antiviral effects of LA were first proposed by Baur and colleagues in 1991 [34]. They observed that the addition of LA to the T-cell lines Jurkat, SupT1, and Molt-4 incubated with a wild-type HIV-1 isolate was associated with dose-dependent inhibition of HIV-1-replication, a reduced cytopathic effect, and the inhibition of reverse transcriptase activity and plaque formation [34]. Moreover, LA synergized with zidovudine in inhibiting viral replication by affecting the reverse transcriptase enzyme [34].
In HIV patients, the administration of LA was associated with positive effects characterized by the stable restoration of the total blood GSH levels and lymphocyte function in comparison to the placebo group, where a progressive decline was observed [35].
In another clinical study, upon the oral administration of LA to 11 AIDS patients, an increase in the blood concentrations of ascorbic acid and total GSH and a decrease in the levels of lipid peroxidation, accompanied by a significant increase in the CD4/CD8 ratio and the number of CD4 + T cells in the plasma, was observed [36].

2.5. Effects of LA in COVID-19

The severity of COVID-19 seems to depend on the massive release of proinflammatory cytokines, including interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, TNF-α, and chemokines such as CXC-chemokine ligand 10 (CXCL10) and CC-chemokine ligand 2 (CCL2), known as the “cytokine storm”. This is likely to promote a self-sustained inflammatory reaction that may ultimately lead to the development of respiratory and multiple organ failure, with a consequent shock and disseminated intravascular coagulation. Besides the respiratory system, SARS-CoV-2 affects other organs, including the heart, kidneys, and the central nervous system. Indeed, COVID-19 patients may have elevated serum creatinine levels, proteinuria, and hematuria and can develop neurological symptoms, such as headaches, parkinsonism, and anosmia. In addition, a thrombogenic diathesis, characterized by the elevation of D-dimer and other procoagulant parameters, can be observed and may be responsible for some lethal cases of COVID-19 [37][38][39][40][41][42][43].
Several lines of evidence suggest the potential beneficial effects of LA in SARS-CoV-2 infection. Indeed, the affinity of SARS-CoV-2 for the ACE2 receptor is augmented by the oxidation of the cysteine residues in the S protein (RBD) of the virus and the cell membrane ACE2 (peptidase domain). Hence, the imbalance of redox homeostasis could represent a major factor favoring SARS-CoV-2 infection [44]. Therefore, it is likely that the cell entry of SARS-CoV-2 could be impaired in the presence of the LA treatment. In addition, by reducing the ROS levels, LA can exert an anti-inflammatory effect, decreasing the proinflammatory cytokine secretion. Additionally, by maintaining an endogen high GSH/GSSG ratio, LA may prevent severe forms of COVID-19. The GSH levels decrease in COVID-19 due to a deficient nuclear translocation of Nrf2 [45]. LA promotes GSH synthesis by increasing the cellular cysteine uptake, a rate-limiting factor for GSH synthesis, and by activating the Nf2-ARE signaling pathways, with increased activity of glutamate-cysteine ligase, the rate-limiting enzyme in GSH production [45]. Finally, given the key contribution of mitochondrial dysfunction in COVID-19 pathogenesis [46], LA is thought to be able to reduce mitochondrial oxidative damage, as it functions as a cofactor for α-ketoglutarate dehydrogenase, a sensor of the mitochondrial redox status that regulates the mitochondrial cytochrome c release and cell death. A report, still in the phase of scientific evaluation, shows the results from a randomized, single-blind trial performed at Jin Yin Tan Hospital, Wuhan, China that enrolled 17 patients with critically ill COVID-19, who were assigned in a 1:1 ratio to receive either LA (1200 mg/d, intravenous) once-daily plus the standard care or the standard care plus an equal volume of saline infusion (placebo) for 7 days. In accordance with the above-mentioned hypotheses, LA was associated with a lower SOFA score increase with respect to the baseline, and a two-fold higher mortality rate was observed in the placebo group, as compared to the LA group. Although the results are encouraging, larger cohorts of patients are needed to validate the efficacy of LA in COVID-19 [47].

This entry is adapted from the peer-reviewed paper 10.3390/antiox10081294

References

  1. Packer, L.; Cadenas, E. Lipoic acid: Energy metabolism and redox regulation of transcription and cell signaling. J. Clin. Biochem. Nutr. 2011, 48, 26–32.
  2. Bustamante, J.; Lodge, J.K.; Marcocci, L.; Tritschler, H.J.; Packer, L.; Rihn, B.H. α-lipoic acid in liver metabolism and disease. Free Radic. Biol. Med. 1998, 24, 1023–1039.
  3. Clavreul, N.; Bachschmid, M.M.; Hou, X.; Shi, C.; Idrizovic, A.; Ido, Y.; Pimentel, D.; Cohen, R.A. S-glutathiolation of p21ras by peroxynitrite mediates endothelial insulin resistance caused by oxidized low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2454–2461.
  4. Ibrahimpasic, K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med. Arch. 2013, 67, 7–9.
  5. Hofmann, M.A.; Schiekofer, S.; Kanitz, M.; Klevesath, M.S.; Joswig, M.; Lee, V.; Morcos, M.; Tritschler, H.; Ziegler, R.; Wahl, P.; et al. Insufficient glycemic control increases nuclear factor-κB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998, 21, 1310–1316.
  6. Ziegler, D.; Reljanovic, M.; Mehnert, H.; Gries, F.A. α-lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes 1999, 107, 421–430.
  7. Nagamatsu, M.; Nickander, K.K.; Schmelzer, J.D.; Raya, A.; Wittrock, D.A.; Tritschler, H.; Low, P.A. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995, 18, 1160–1167.
  8. Androne, L.; Gavan, N.A.; Veresiu, I.A.; Orasan, R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000, 14, 327–330.
  9. Packer, L.; Kraemer, K.; Rimbach, G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001, 17, 888–895.
  10. Jones, W.; Li, X.; Qu, Z.; Perriott, L.; Whitesell, R.R.; May, J.M. Uptake, recycling, and antioxidant actions of α-lipoic acid in endothelial cells. Free Radic. Biol. Med. 2002, 33, 83–93.
  11. Ziegler, D.; Gries, F.A. α-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997, 46, S62–S66.
  12. Lynch, M.A. Lipoic acid confers protection against oxidative injury in non-neuronal and neuronal tissue. Nutr. Neurosci. 2001, 4, 419–438.
  13. Tancheva, L.P.; Lazarova, M.I.; Alexandrova, A.V.; Dragomanova, S.T.; Nicoletti, F.; Tzvetanova, E.R.; Hodzhev, Y.K.; Kalfin, R.E.; Miteva, S.A.; Mazzon, E.; et al. Neuroprotective mechanisms of three natural antioxidants on a rat model of parkinson’s disease: A comparative study. Antioxidants 2020, 9, 49.
  14. Tzvetanova, E.R.; Georgieva, A.P.; Alexandrova, A.V.; Tancheva, L.P.; Lazarova, M.I.; Dragomanova, S.T.; Alova, L.G.; Stefanova, M.O.; Kalfin, R.E. Antioxidant mechanisms in neuroprotective action of lipoic acid on learning and memory of rats with experimental dementia. Bulg. Chem. Commun. 2018, 50, 52–57.
  15. Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Münch, G. Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch. Gerontol. Geriatr. 2001, 32, 275–282.
  16. Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young, S.; Hager, K.; Engel, J.; Münch, G. Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol. Ther. 2007, 113, 154–164.
  17. Lovell, M.A.; Xie, C.; Xiong, S.; Markesbery, W.R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J. Alzheimer’s Dis. 2003, 5, 229–239.
  18. Kim, S.M.; Ha, J.S.; Han, A.R.; Cho, S.W.; Yang, S.J. Effects of α-lipoic acid on LPS-induced neuroinflammation and NLRP3 inflammasome activation through the regulation of BV-2 microglial cells activation. BMB Rep. 2019, 52, 613–618.
  19. Maldonado-Rojas, W.; Olivero-Verbel, J.; Ortega-Zuñiga, C. Searching of protein targets for alpha lipoic acid. J. Braz. Chem. Soc. 2011, 22, 2250–2259.
  20. Khomich, O.A.; Kochetkov, S.N.; Bartosch, B.; Ivanov, A.V. Redox biology of respiratory viral infections. Viruses 2018, 10, 392.
  21. Bai, S.W.; Chen, C.Y.; Ji, J.; Xie, Q.M.; Ma, Y.; Sun, B.L.; Xue, C.Y.; Cao, Y.C.; Ma, J.Y.; Bi, Y.Z. Inhibition Effect of Alpha-Lipoic Acid on the Propagation of Influenza A Virus in MDCK Cells. Pak. Vet. J. 2012, 32, 101–106.
  22. McGeoch, D.J.; Cook, S.; Dolan, A.; Jamieson, F.E.; Telford, E.A.R. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J. Mol. Biol. 1995, 247, 443–458.
  23. Hepatitis viral load correlates to glutathione levels. Posit. Health News 1998, 17, 14–15.
  24. Vendemiale, G.; Grattagliano, I.; Portincasa, P.; Serviddio, G.; Palasciamo, G.; Altomare, E. Oxidative stress in symptom-free HCV carriers: Relation with ALT flare-up. Eur. J. Clin. Investig. 2001, 31, 54–63.
  25. Tanyalcin, T.; Taskiran, D.; Topalak, O.; Batur, Y.; Kutay, F. The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. Hepatol. Res. 2000, 18, 104–109.
  26. Von Herbay, A.; Stahl, W.; Niederau, C.; Von Laar, J.; Strohmeyer, G.; Sies, H. Diminished plasma levels of vitamin E in patients with severe viral hepatitis. Free Radic. Res. 1996, 25, 461–466.
  27. Berkson, B.M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (Thioctic acid), silymarin, and selenium: Three case histories. Med. Klin. 1999, 94, 84–89.
  28. Melhem, A.; Stern, M.; Shibolet, O.; Israeli, E.; Ackerman, Z.; Pappo, O.; Hemed, N.; Rowe, M.; Ohana, H.; Zabrecky, G.; et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. J. Clin. Gastroenterol. 2005, 39, 737–742.
  29. Greenspan, H.C.; Aruoma, O.I. Oxidative stress and apoptosis in HIV infection: A role for plant-derived metabolites with synergistic antioxidant activity. Immunol. Today 1994, 15, 209–213.
  30. Pace, G.W.; Leaf, C.D. The role of oxidative stress in HIV disease. Free Radic. Biol. Med. 1995, 19, 523–528.
  31. Sandstrom, P.A.; Tebbey, R.W.; Van Cleave, S.; Buttke, T.M. Lipid hydroperoxides induce apoptosis in T cells displaying a HIV- associated glutathione peroxidase deficiency. J. Biol. Chem. 1994, 269, 798–801.
  32. Jarstrand, C.; Åkerlund, B. Oxygen radical release by neutrophils of HIV-infected patients. Chem. Biol. Interact. 1994, 91, 141–146.
  33. Polyakov, V.M.; Shepelev, A.P.; Kokovkina, O.E.; Vtornikova, I.V. B15—Superoxide anion (O2−) production and enzymatic disbalance in peripheral blood cells isolated from HIV-infected children. Free Radic. Biol. Med. 1994, 16, 15.
  34. Baur, A.; Harrer, T.; Peukert, M.; Jahn, G.; Kalden, J.R.; Fleckenstein, B. Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. Klin. Wochenschr. 1991, 69, 722–724.
  35. Jariwalla, R.J.; Lalezari, J.; Cenko, D.; Mansour, S.E.; Kumar, A.; Gangapurkar, B.; Nakamura, D. Restoration of blood total glutathione status and lymphocyte function following α-lipoic acid supplementation in patients with HIV infection. J. Altern. Complement. Med. 2008, 14, 139–146.
  36. Studies on Lipoate Effects on Blood Redox State in Human Immunodeficiency Virus Infected Patients—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/8141828/ (accessed on 9 February 2021).
  37. Fagone, P.; Ciurleo, R.; Lombardo, S.D.; Iacobello, C.; Palermo, C.I.; Shoenfeld, Y.; Bendtzen, K.; Bramanti, P.; Nicoletti, F. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun. Rev. 2020, 19, 102571.
  38. Cavalli, E.; Petralia, M.; Basile, M.; Bramanti, A.; Bramanti, P.; Nicoletti, F.; Spandidos, D.; Shoenfeld, Y.; Fagone, P. Transcriptomic analysis of COVID-19 lungs and bronchoalveolar lavage fluid samples reveals predominant B cell activation responses to infection. Int. J. Mol. Med. 2020, 46, 1266–1273.
  39. Tancheva, L.; Petralia, M.C.; Miteva, S.; Dragomanova, S.; Solak, A.; Kalfin, R.; Lazarova, M.; Yarkov, D.; Ciurleo, R.; Cavalli, E.; et al. Emerging neurological and psychobiological aspects of COVID-19 infection. Brain Sci. 2020, 10, 852.
  40. Cavalli, E.; Bramanti, A.; Ciurleo, R.; Tchorbanov, A.I.; Giordano, A.; Fagone, P.; Belizna, C.; Bramanti, P.; Shoenfeld, Y.; Nicoletti, F. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). Int. J. Mol. Med. 2020, 46, 903–912.
  41. Sturley, S.L.; Rajakumar, T.; Hammond, N.; Higaki, K.; Márka, Z.; Márka, S.; Munkacsi, A.B. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity. J. Lipid Res. 2020, 61, 972–982.
  42. Caterino, M.; Gelzo, M.; Sol, S.; Fedele, R.; Annunziata, A.; Calabrese, C.; Fiorentino, G.; D’Abbraccio, M.; Dell’Isola, C.; Fusco, F.M.; et al. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. Sci. Rep. 2021, 11, 2941.
  43. Abu-Farha, M.; Thanaraj, T.A.; Qaddoumi, M.G.; Hashem, A.; Abubaker, J.; Al-Mulla, F. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. Int. J. Mol. Sci. 2020, 21, 3544.
  44. Suhail, S.; Zajac, J.; Fossum, C.; Lowater, H.; McCracken, C.; Severson, N.; Laatsch, B.; Narkiewicz-Jodko, A.; Johnson, B.; Liebau, J.; et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein J. 2020, 39, 644–656.
  45. Guloyan, V.; Oganesian, B.; Baghdasaryan, N.; Yeh, C.; Singh, M.; Guilford, F.; Ting, Y.S.; Venketaraman, V. Glutathione supplementation as an adjunctive therapy in COVID-19. Antioxidants 2020, 9, 914.
  46. Pagano, G.; Manfredi, C.; Pallardó, F.V.; Lyakhovich, A.; Tiano, L.; Trifuoggi, M. Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia. Inflamm. Res. 2021, 70, 159–170.
  47. Zhong, M.; Sun, A.; Xiao, T.; Yao, G.; Sang, L.; Zheng, X.; Zhang, J.; Jin, X.; Xu, L.; Yang, W.; et al. A Randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). medRxiv 2020.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Feedback